Health

Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy

0
Positive Phase 3 Trial in hATTR Amyloidosis With Polyneuropathy

The RNAi therapeutic vutrisiran met its primary and secondary endpoints in the HELIOS-A phase 3 study of patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy. Medscape Medical News
Read More

admin

Sickle-Cell Trait May Not Independently Elevate CHD Risk

Previous article

Sinovac, AstraZeneca seek vaccine approval in Brazil

Next article

You may also like

Comments

Leave a reply

Your email address will not be published. Required fields are marked *

More in Health